TuHURA Biosciences (HURA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
24 Aug, 2026Opening remarks and agenda
The meeting was called to order virtually, with instructions for participation and voting provided to stockholders.
Dr. Jim Bianco, President and CEO, served as Chairman and Secretary, confirming the meeting's official start and the opening of polls.
Board and executive committee updates
Six directors were nominated for election to serve until the 2027 annual meeting or until successors are qualified.
Shareholder proposals
Proposals included director elections, approval of share issuance to Parkview Holdings One LLC, advisory votes on executive compensation and its frequency, ratification of the independent auditor, and potential adjournment.
The Board recommended a three-year frequency for advisory votes on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from TuHURA Biosciences
- Q2 2026 net loss was $9.2M; cash at $1.0M; $50M credit facility extends runway into 2028.HURA
Q2 2026 - Advancing phase III immunotherapy for Merkel cell carcinoma with FDA SPA and novel AML programs.HURA
Canaccord Genuity's 46th Annual Growth Conference - Advancing late-stage immuno-oncology assets to overcome resistance in cancer treatment.HURA
Corporate presentation - Virtual meeting to elect directors, approve share issuance, and ratify auditor on August 18, 2026.HURA
Proxy filing - Shareholders to vote on director elections, major share issuance, and executive pay; board recommends approval.HURA
Proxy filing - Shareholders will vote on director elections, share issuance, compensation, and auditor ratification.HURA
Proxy filing - Clinical-stage immuno-oncology firm expands pipeline via merger, but faces ongoing financial and execution risks.HURA
Registration filing - Diversified immuno-oncology pipeline advances amid ongoing losses and high funding needs.HURA
Registration filing - Up to $250M in securities registered, including $50M ATM, to fund oncology pipeline and operations.HURA
Registration filing